{"organizations": [], "uuid": "08c8cd63b1987f9af8da3d248d683c70f869b0cd", "thread": {"social": {"gplus": {"shares": 0}, "pinterest": {"shares": 0}, "vk": {"shares": 0}, "linkedin": {"shares": 0}, "facebook": {"likes": 0, "shares": 0, "comments": 0}, "stumbledupon": {"shares": 0}}, "site_full": "www.reuters.com", "main_image": "https://s4.reutersmedia.net/resources_v2/images/rcom-default.png", "site_section": "http://feeds.reuters.com/reuters/companyNews\r", "section_title": "Reuters: Company News", "url": "https://www.reuters.com/article/brief-momenta-pharmaceuticals-announces/brief-momenta-pharmaceuticals-announces-fda-approval-and-launch-of-glatopa-idUSASB0C5C5", "country": "US", "domain_rank": 408, "title": "BRIEF-Momenta Pharmaceuticals Announces FDA Approval And Launch Of Glatopa", "performance_score": 0, "site": "reuters.com", "participants_count": 0, "title_full": "", "spam_score": 0.0, "site_type": "news", "published": "2018-02-13T08:22:00.000+02:00", "replies_count": 0, "uuid": "08c8cd63b1987f9af8da3d248d683c70f869b0cd"}, "author": "", "url": "https://www.reuters.com/article/brief-momenta-pharmaceuticals-announces/brief-momenta-pharmaceuticals-announces-fda-approval-and-launch-of-glatopa-idUSASB0C5C5", "ord_in_thread": 0, "title": "BRIEF-Momenta Pharmaceuticals Announces FDA Approval And Launch Of Glatopa", "locations": [], "entities": {"persons": [], "locations": [{"name": "u.s.", "sentiment": "none"}, {"name": "us", "sentiment": "none"}], "organizations": [{"name": "brief-momenta pharmaceuticals announces fda", "sentiment": "negative"}, {"name": "momenta pharmaceuticals inc", "sentiment": "none"}, {"name": "glatopa reuters", "sentiment": "none"}, {"name": "fda", "sentiment": "none"}, {"name": "sandoz", "sentiment": "none"}, {"name": "bengaluru newsroom", "sentiment": "none"}, {"name": "momenta pharmaceuticals", "sentiment": "none"}, {"name": "reuters", "sentiment": "none"}, {"name": "eikon", "sentiment": "none"}, {"name": "momenta", "sentiment": "none"}]}, "highlightText": "", "language": "english", "persons": [], "text": "Feb 13 (Reuters) - Momenta Pharmaceuticals Inc:\n* MOMENTA PHARMACEUTICALS ANNOUNCES FDA APPROVAL AND LAUNCH OF GLATOPA® (GLATIRAMER ACETATE INJECTION) 40 MG/ML\n* MOMENTA PHARMACEUTICALS- U.S. FDA HAS APPROVED SANDOZ‘S ABBREVIATED NEW DRUG APPLICATION FOR GLATOPA (GLATIRAMER ACETATE INJECTION) 40 MG/ML​\n* MOMENTA PHARMACEUTICALS - SANDOZ INITIATED LAUNCH OF THE PRODUCT IN U.S.\n* MOMENTA PHARMACEUTICALS - GLATOPA WAS DEVELOPED UNDER A COLLABORATION AGREEMENT BETWEEN MOMENTA AND SANDOZ AND IS PRODUCED IN THE US Source text for Eikon: Further company coverage: (Bengaluru Newsroom)\n ", "external_links": [], "published": "2018-02-13T08:22:00.000+02:00", "crawled": "2018-02-13T08:33:06.002+02:00", "highlightTitle": ""}